Quality of life assessment in a chemoprevention trial: Fenretinide and oral or transdermal HRT

Research output: Contribution to journalArticle

Abstract

Background: Oral conjugated equine estrogen (CEE) and medroxyprogesterone acetate (MPA) relief menopause symptoms, but may increase breast cancer risk, while the effects of transdermal estradiol (E2) and MPA are less known. In previous studies, fenretinide decreased second breast malignancies in premenopausal but not in postmenopausal women, suggesting a hormone-sensitizing effect. We have evaluated the quality of life through a self-administered questionnaire during a randomized study of oral CEE or transdermal E2 and fenretinide or placebo. Methods: A total of 226 postmenopausal women were randomly assigned to either CEE 0.625 mg/day and placebo (n = 55), or CEE and fenretinide 100 mg/bid (n = 56), or E2, 50 μg/day and placebo (n = 59), or E2 and fenretinide (n = 56) for 12 months. Sequential MPA 10 mg/day was added in all groups. Treatment effects were investigated using a validated questionnaire, the Menopause Quality of Life questionnaire (MENQOL). Results: Oral CEE and transdermal E2 have a comparable activity in reducing menopausal symptoms (p = ns). Both routes ameliorate significantly the symptoms after 1 year of treatment (p <0.0001). Fenretinide does not modify the effects of hormonal replacement therapy. Conclusions: Oral CEE and transdermal E2 have similar effect on menopausal symptoms relief. The choice of the best estrogen replacement therapy (ERT) route should be decided based on a careful analysis of all the clinical aspects of every subject, considering that transdermal therapy may have a safer effect on the cardiovascular system.

Original languageEnglish
Pages (from-to)69-75
Number of pages7
JournalMaturitas
Volume55
Issue number1
DOIs
Publication statusPublished - Aug 20 2006

Fingerprint

Fenretinide
Conjugated (USP) Estrogens
Chemoprevention
Quality of Life
Medroxyprogesterone Acetate
Placebos
Menopause
Cardiovascular system
Estrogen Replacement Therapy
Second Primary Neoplasms
Therapeutics
Cardiovascular System
Estradiol
Estrogens
Breast
Hormones
Breast Neoplasms

Keywords

  • Breast neoplasms
  • Chemoprevention
  • Estrogen replacement therapy
  • Fenretinide
  • Menopause symptoms and quality of life

ASJC Scopus subject areas

  • Ageing
  • Obstetrics and Gynaecology

Cite this

Quality of life assessment in a chemoprevention trial : Fenretinide and oral or transdermal HRT. / Serrano, Davide; Mariani, Luigi; Mora, Serena; Guerrieri-Gonzaga, Aliana; Cazzaniga, Massimiliano; Daldoss, Cristina; Ramazzotto, Francesca; Feroce, Irene; Decensi, Andrea; Bonanni, Bernardo.

In: Maturitas, Vol. 55, No. 1, 20.08.2006, p. 69-75.

Research output: Contribution to journalArticle

@article{1fba61e5e684412881ccec65531aa81f,
title = "Quality of life assessment in a chemoprevention trial: Fenretinide and oral or transdermal HRT",
abstract = "Background: Oral conjugated equine estrogen (CEE) and medroxyprogesterone acetate (MPA) relief menopause symptoms, but may increase breast cancer risk, while the effects of transdermal estradiol (E2) and MPA are less known. In previous studies, fenretinide decreased second breast malignancies in premenopausal but not in postmenopausal women, suggesting a hormone-sensitizing effect. We have evaluated the quality of life through a self-administered questionnaire during a randomized study of oral CEE or transdermal E2 and fenretinide or placebo. Methods: A total of 226 postmenopausal women were randomly assigned to either CEE 0.625 mg/day and placebo (n = 55), or CEE and fenretinide 100 mg/bid (n = 56), or E2, 50 μg/day and placebo (n = 59), or E2 and fenretinide (n = 56) for 12 months. Sequential MPA 10 mg/day was added in all groups. Treatment effects were investigated using a validated questionnaire, the Menopause Quality of Life questionnaire (MENQOL). Results: Oral CEE and transdermal E2 have a comparable activity in reducing menopausal symptoms (p = ns). Both routes ameliorate significantly the symptoms after 1 year of treatment (p <0.0001). Fenretinide does not modify the effects of hormonal replacement therapy. Conclusions: Oral CEE and transdermal E2 have similar effect on menopausal symptoms relief. The choice of the best estrogen replacement therapy (ERT) route should be decided based on a careful analysis of all the clinical aspects of every subject, considering that transdermal therapy may have a safer effect on the cardiovascular system.",
keywords = "Breast neoplasms, Chemoprevention, Estrogen replacement therapy, Fenretinide, Menopause symptoms and quality of life",
author = "Davide Serrano and Luigi Mariani and Serena Mora and Aliana Guerrieri-Gonzaga and Massimiliano Cazzaniga and Cristina Daldoss and Francesca Ramazzotto and Irene Feroce and Andrea Decensi and Bernardo Bonanni",
year = "2006",
month = "8",
day = "20",
doi = "10.1016/j.maturitas.2006.01.005",
language = "English",
volume = "55",
pages = "69--75",
journal = "Maturitas",
issn = "0378-5122",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Quality of life assessment in a chemoprevention trial

T2 - Fenretinide and oral or transdermal HRT

AU - Serrano, Davide

AU - Mariani, Luigi

AU - Mora, Serena

AU - Guerrieri-Gonzaga, Aliana

AU - Cazzaniga, Massimiliano

AU - Daldoss, Cristina

AU - Ramazzotto, Francesca

AU - Feroce, Irene

AU - Decensi, Andrea

AU - Bonanni, Bernardo

PY - 2006/8/20

Y1 - 2006/8/20

N2 - Background: Oral conjugated equine estrogen (CEE) and medroxyprogesterone acetate (MPA) relief menopause symptoms, but may increase breast cancer risk, while the effects of transdermal estradiol (E2) and MPA are less known. In previous studies, fenretinide decreased second breast malignancies in premenopausal but not in postmenopausal women, suggesting a hormone-sensitizing effect. We have evaluated the quality of life through a self-administered questionnaire during a randomized study of oral CEE or transdermal E2 and fenretinide or placebo. Methods: A total of 226 postmenopausal women were randomly assigned to either CEE 0.625 mg/day and placebo (n = 55), or CEE and fenretinide 100 mg/bid (n = 56), or E2, 50 μg/day and placebo (n = 59), or E2 and fenretinide (n = 56) for 12 months. Sequential MPA 10 mg/day was added in all groups. Treatment effects were investigated using a validated questionnaire, the Menopause Quality of Life questionnaire (MENQOL). Results: Oral CEE and transdermal E2 have a comparable activity in reducing menopausal symptoms (p = ns). Both routes ameliorate significantly the symptoms after 1 year of treatment (p <0.0001). Fenretinide does not modify the effects of hormonal replacement therapy. Conclusions: Oral CEE and transdermal E2 have similar effect on menopausal symptoms relief. The choice of the best estrogen replacement therapy (ERT) route should be decided based on a careful analysis of all the clinical aspects of every subject, considering that transdermal therapy may have a safer effect on the cardiovascular system.

AB - Background: Oral conjugated equine estrogen (CEE) and medroxyprogesterone acetate (MPA) relief menopause symptoms, but may increase breast cancer risk, while the effects of transdermal estradiol (E2) and MPA are less known. In previous studies, fenretinide decreased second breast malignancies in premenopausal but not in postmenopausal women, suggesting a hormone-sensitizing effect. We have evaluated the quality of life through a self-administered questionnaire during a randomized study of oral CEE or transdermal E2 and fenretinide or placebo. Methods: A total of 226 postmenopausal women were randomly assigned to either CEE 0.625 mg/day and placebo (n = 55), or CEE and fenretinide 100 mg/bid (n = 56), or E2, 50 μg/day and placebo (n = 59), or E2 and fenretinide (n = 56) for 12 months. Sequential MPA 10 mg/day was added in all groups. Treatment effects were investigated using a validated questionnaire, the Menopause Quality of Life questionnaire (MENQOL). Results: Oral CEE and transdermal E2 have a comparable activity in reducing menopausal symptoms (p = ns). Both routes ameliorate significantly the symptoms after 1 year of treatment (p <0.0001). Fenretinide does not modify the effects of hormonal replacement therapy. Conclusions: Oral CEE and transdermal E2 have similar effect on menopausal symptoms relief. The choice of the best estrogen replacement therapy (ERT) route should be decided based on a careful analysis of all the clinical aspects of every subject, considering that transdermal therapy may have a safer effect on the cardiovascular system.

KW - Breast neoplasms

KW - Chemoprevention

KW - Estrogen replacement therapy

KW - Fenretinide

KW - Menopause symptoms and quality of life

UR - http://www.scopus.com/inward/record.url?scp=33746266622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746266622&partnerID=8YFLogxK

U2 - 10.1016/j.maturitas.2006.01.005

DO - 10.1016/j.maturitas.2006.01.005

M3 - Article

C2 - 16500052

AN - SCOPUS:33746266622

VL - 55

SP - 69

EP - 75

JO - Maturitas

JF - Maturitas

SN - 0378-5122

IS - 1

ER -